LA JOLLA, Calif.–(BUSINESS WIRE)–Trio Health, a leading provider of retrospective observational data on real world patients, today announced results from several of its research programs that reveal critical, and often counterintuitive, insights rega… […]
Novartis has agreed to pay $150 million to Ionis Pharmaceuticals and Boston-based Akcea Therapeutics for the rights to a clinical-stage drug meant to treat patients with abnormally high levels of a protein that is considered a risk factor for cardiovas… […]
LA JOLLA?The Salk Institute Board of Trustees is pleased to announce its two newest members, David Dolby and Mark Knickrehm, both innovative leaders in business and technology.
The post Technology and business giants David Dolby and Mark Knickrehm join… […]
Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. The decision sets Novartis up to test the RNA-targeting drug in […]
Novartis will pay $150 million to license a heart disease medication discovered by Carlsbad?s Ionis Pharmaceuticals, the Swiss drug giant said Monday. The experimental drug was co-developed by Ionis with its majority-owned subsidiary Akcea Therapeu… […]
Section 32, the venture capital fund based in San Diego?s Cardiff-by-the-Sea community, has raised nearly $200 million for its second fund. A document filed with securities regulators Friday shed light on comments made the previous week to Xconomy by S… […]
SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/OSA?src=hash" target="_blank"gt;#OSAlt;/agt;–New work leveraging machine learning could increase the efficiency of optical telecommunications networks. As our world… […]